In light of recent news on bacterial resistance, Derek Lowe wonders if we have to re-think the antibacterial medication paradigm:
. . . researchers will have to rethink their attitudes towards antiinfective drugs. For serious infections, we’re going to have to think about these projects the way we’ve traditionally thought of oncology agents – last-ditch therapies for deadly conditions. Anticancer therapies have long had more latitude in their side effects, therapeutic ratios, and dosing regimes, and antibiotics for resistant infections are in the same position.
